KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2025)

Adaptive Biotechnologies' Cost of Revenue history spans 8 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 90.79% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $71.4 million, down 1.0%, while the annual FY2025 figure was $71.4 million, 1.0% down from the prior year.
  • Cost of Revenue for Q4 2025 was $1.3 million at Adaptive Biotechnologies, down from $35.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $35.1 million in Q3 2025 and bottomed at -$19.5 million in Q4 2021.
  • The 5-year median for Cost of Revenue is $19.9 million (2023), against an average of $15.8 million.
  • The largest annual shift saw Cost of Revenue crashed 785.31% in 2021 before it surged 7360.0% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at -$19.5 million in 2021, then soared by 151.28% to $10.0 million in 2022, then soared by 119.43% to $21.9 million in 2023, then tumbled by 37.11% to $13.8 million in 2024, then crashed by 90.79% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Cost of Revenue are $1.3 million (Q4 2025), $35.1 million (Q3 2025), and $18.0 million (Q2 2025).